Teva Pharmaceutical Industries (LTS:0LER) Ending Cash Position : $3,300 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Teva Pharmaceutical Industries Ending Cash Position?

Teva Pharmaceutical Industries's Ending Cash Position for the quarter that ended in Dec. 2024 was $3,300 Mil.

Teva Pharmaceutical Industries's quarterly Ending Cash Position increased from Jun. 2024 ($2,258 Mil) to Sep. 2024 ($3,319 Mil) but then declined from Sep. 2024 ($3,319 Mil) to Dec. 2024 ($3,300 Mil).

Teva Pharmaceutical Industries's annual Ending Cash Position increased from Dec. 2022 ($2,834 Mil) to Dec. 2023 ($3,227 Mil) and increased from Dec. 2023 ($3,227 Mil) to Dec. 2024 ($3,300 Mil).

Teva Pharmaceutical Industries Ending Cash Position Historical Data

The historical data trend for Teva Pharmaceutical Industries's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Ending Cash Position Chart

Teva Pharmaceutical Industries Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

2,177.00

2,198.00

2,834.00

3,227.00

3,300.00

Teva Pharmaceutical Industries Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															3,227.00	2,991.00	2,258.00	3,319.00	3,300.00

Teva Pharmaceutical Industries Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Teva Pharmaceutical Industries's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	3226	+	74
	=	3,300

Teva Pharmaceutical Industries's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	3318	+	-18
	=	3,300

Teva Pharmaceutical Industries Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (LTS:0LER) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

TEVJF:USA TEVA:USA TEVA N:Mexico TEVA:Israel TEV:Germany TEV:Germany TEV:Germany T1EV34:Brazil TEV:Bulgaria TEVA:Austria

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Teva Pharmaceutical Industries Headlines

No Headlines